TY - JOUR
T1 - Antimicrobial peptides for tackling cystic fibrosis related bacterial infections: A review
AU - Bugli, Francesca
AU - Martini, Cecilia
AU - Di Vito, Maura
AU - Cacaci, Margherita
AU - Catalucci, Daniele
AU - Gori, Alessandro
AU - Iafisco, Michele
AU - Sanguinetti, Maurizio
AU - Vitali, Alberto
PY - 2022
Y1 - 2022
N2 - Antibiotic resistance is a serious health and social problem that will have a substantial impact in the coming years on the world health and economy. Thus, the increasing demand for innovative antibiotics, has prompted many researchers in the medical, microbiological, and biochemical fields to exploit the properties of antimicrobial peptides (AMPs). When properly used, designed, and conveyed, AMPs can really represent a valid alternative to conventional drugs especially in situations that are particularly difficult to treat such as chronic infections found in Cystic Fibrosis (CF) patients. In this review we focused on the applications of AMPs in the specific field of CF, illustrating different types of peptides from natural, naturally modified, synthetic as well as the different strategies used to overcome the barriers, and the physiological conditions in which AMPs must operate.
AB - Antibiotic resistance is a serious health and social problem that will have a substantial impact in the coming years on the world health and economy. Thus, the increasing demand for innovative antibiotics, has prompted many researchers in the medical, microbiological, and biochemical fields to exploit the properties of antimicrobial peptides (AMPs). When properly used, designed, and conveyed, AMPs can really represent a valid alternative to conventional drugs especially in situations that are particularly difficult to treat such as chronic infections found in Cystic Fibrosis (CF) patients. In this review we focused on the applications of AMPs in the specific field of CF, illustrating different types of peptides from natural, naturally modified, synthetic as well as the different strategies used to overcome the barriers, and the physiological conditions in which AMPs must operate.
KW - Antibiotic Resistance
KW - Antimicrobial Peptides
KW - Biofilm
KW - Cystic Fibrosis
KW - Drug Delivery
KW - Nanoparticles
KW - Antibiotic Resistance
KW - Antimicrobial Peptides
KW - Biofilm
KW - Cystic Fibrosis
KW - Drug Delivery
KW - Nanoparticles
UR - http://hdl.handle.net/10807/232125
U2 - 10.1016/j.micres.2022.127152
DO - 10.1016/j.micres.2022.127152
M3 - Article
SN - 0944-5013
VL - 263
SP - 1
EP - 16
JO - Microbiological Research
JF - Microbiological Research
ER -